A Phase II, Prospective, 24 Weeks, Double-blind, Placebo-controlled, Randomized, Multi-center Clinical Trial for the Evaluation of the Efficacy and Safety of DW1029M on Microalbuminuria in Patients With Diabetic Nephropathy

Trial Profile

A Phase II, Prospective, 24 Weeks, Double-blind, Placebo-controlled, Randomized, Multi-center Clinical Trial for the Evaluation of the Efficacy and Safety of DW1029M on Microalbuminuria in Patients With Diabetic Nephropathy

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Feb 2017

At a glance

  • Drugs DW 1029M (Primary)
  • Indications Diabetic nephropathies; Proteinuria
  • Focus Therapeutic Use
  • Acronyms DW1029M
  • Sponsors Dong Wha Pharmaceutical
  • Most Recent Events

    • 11 Feb 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 06 Aug 2014 Planned End Date changed from 1 Oct 2014 to 1 Feb 2015 as reported by ClinicalTrials.gov.
    • 28 Apr 2014 Status changed from not yet recruiting to recruiting as reported by Clinical Research Information Service (CriS) - Republic of Korea record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top